Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China

Table 1 Baseline clinical data between hepatitis B virus core antibody positive and hepatitis B virus core antibody negative liver graft recipients

Factor	Before propensity matching			After propensity matching
	HBcAb+ (n = 230)	HBcAb- (n = 841)	P value	HBcAb+ (n = 210)	HBcAb- (n = 210)	P value
Baseline characteristic
Gender (male)	77.4% (178)	80.10% (674)	0.36	80.5% (169)	79.5% (167)	0.90
Age (yr)	41.03 ± 15.58	42.04 ± 15.19	0.63	40.67 ± 16.57	40.55 ± 15.47	0.94
BMI	22.1 (19.7-24.2)	22.0 (19.8-24.4)	0.54	22.4 (19.7-24.4)	22.2 (19.7-24.2)	0.8
MELD	13.0 (9.0-21.0)	13.0 (9.0-20.0)	0.62	14.5 (10.0-20.8)	13.0 (9.0-20.0)	0.25
CTP	9.0 (7.0-11.0)	8.0 (7.0-10.0)	< 0.01	9.0 (7.0-11.0)	9.0 (7.0-11.0)	0.14
Creatinine (µmol/L)	67.0 (53.1-81.9)	71.9 (59.3-85.3)	< 0.01	68.4 (55.9-82.6)	67.5 (53.6-82.4)	0.36
Total bilirubin (µmol/L)	43.2 (18.8-198.3)	37.8 (18.9-139.9)	0.31	51.2 (22.8-201.9)	40.2 (18.6-195.0)	0.20
Albumin (g/L)	35.4 (30.9-40.5)	34.6 (30.1-40.1)	0.11	33.8 (30.1-40.1)	35.4 (31.1-41.3)	0.06
HBV-positive	64.78% (149)	77.28% (650)	< 0.01	62.9% (132)	69.0% (145)	0.18
HCV-positive	1.3% (3)	7.4% (62)	< 0.01	0.95% (2)	3.33% (7)	0.18
Etiology
Liver cancer	48.26% (111)	46.13% (388)	0.57	43.3% (91)	49.5% (104)	0.20
Acute liver failure	11.30% (26)	4.99% (42)	< 0.01	8.57% (18)	11.4% (24)	0.32
Cirrhosis
Biliary	9.13% (21)	7.84% (66)	0.53	8.57% (18)	9.05% (19)	0.86
HBV related	49.13% (113)	55.41% (466)	0.09	56.19% (118)	54.76% (15)	0.76
HCV related	0.86% (2)	1.90% (16)	0.28	0.95% (2)	2.38% (5)	0.45
Alcoholic	2.17% (5)	3.21% (27)	0.41	1.90% (4)	0.95% (2)	0.69
Autoimmune	1.74% (4)	1.07% (9)	0.41	0.95% (2)	0.95% (2)	1.00
Donor
Gender (male)	74.35% (171)	79.30% (666)	0.12	61.4% (129)	61.9% (130)	0.92
Age	41.28 ± 13.01	33.66 ± 10.16	< 0.01	39.08 ± 10.59	40.82 ± 12.36	0.12
BMI	22.7 (20.8-24.6)	22.2 (20.8-23.9)	0.06	22.8 (21.4-24.8)	22.6 (20.8-24.5)	0.37
Serum Na+ (mmol/L)	143.0 (140.1-153.6)	139.9 (136.2-142.7)	< 0.01	141.6 (138.5-143.9)	141.9 (140.0-153.5)	0.23
Creatinine (µmol/L)	73.1 (54.5-98.5)	74.6 (62.8-84.6)	< 0.01	75.3 (63.0-88.5)	74.4 (54.0-95.6)	0.39
Total bilirubin (µmol/L)	13.8 (9.4-18.9)	15.1 (10.2-23.3)	0.05	14.9 (10.1-21.7)	13.8 (9.4-18.7)	0.25
Albumin (g/L)	40.3 (32.6-45.3)	41.9 (36.2-46.6)	0.06	42.1 (36.2-46.7)	41.8 (34.9-46.0)	0.12
ALT (IU/L)	23.0 (16.0-45.0)	28.0 (16.0-47.0)	0.32	27.0 (17.8-46.2)	26.0 (16.0-43.0)	0.10
AST (IU/L)	27.0 (20.8-42.0)	26.0 (18.0-39.0)	0.15	27.0 (19.0-39.8)	27.5 (20.0-47.0)	0.12
Cold ischemic time (h)	5.0 (3.2-7.8)	6.0 (5.0-10.0)	0.05	5.5 (4.0-8.0)	5.5 (3.0-7.0)	0.11
Warm ischemic time (min)	6.0 (3.0-9.0)	4.5 (2.0-6.5)	0.05	6.0 (3.0-10.0)	5.0 (3.0-7.0)	0.08

Data are shown as the mean ± SD or medians with 25^th-75^th interquartile ranges when presenting significant differences from the normal distribution. For continuous variables, either the Mann-Whitney U-test or Student’s-t test was performed, and the differences between rates were tested by Chi square test or Fisher exact test, if appropriate. CTP: Child-Pugh score; ALT: Glutamic-pyruvic transaminase; AST: Glutamic oxaloacetic transaminase; MELD: Model for end-stage liver disease.